series-a
Stage
1
Investors
About
InterAx Biotech AG develops novel small molecule drugs targeting G protein-coupled receptors (GPCRs) by using its Deep Signal™ platform, which integrates mathematical modeling, experimental methods, and machine learning to better understand cellular signaling and improve drug efficacy and safety.
Explore InterAx Biotech AG's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.